Inducible nitric oxide synthase expression in human vein grafts

Jeffery Dattilo, Mary Peace M. Dattilo, John A. Spratt, John Matsuura, Dorne R. Yager, Raymond G. Makhoul

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    BACKGROUND: The patency of vascular reconstructive procedures is limited by the development of intimal hyperplasia (IH). Nitric oxide (NO) seems to be beneficial in abrogating this process. Currently, there is little information concerning inducible nitric oxide synthase (INOS), the enzyme responsible for NO synthesis, and human vein grafts. The purpose of this study was to examine iNOS gene expression in human aortocoronary vein grafts (ACVG) and infrainguinal vein bypass grafts (IVG). METHODS: Nonthrombosed sections from ACVG (n = 5), IVG (n = 5), and control saphenous vein (SV; n = 4) were harvested and processed for RNA isolation. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was performed on samples using 32P radioactively end labeled primers. Glyceraldehyde-3- phosphatedehydrogenase (GAPDH) was the internal control, and results were expressed as iNOS pmol/ GAPDH pmol. RESULTS: There was a significant increase in the iNOS gene expression in the ACVG (0.049 ± 0.01) when compared with IVG (0.019 ± 0.001) or normal SV (0.011 ± 0.002; P ≤0.05). There was no significant difference between normal vein and the infrainguinal grafts. Sequencing of a fragment of the amplified 428 bp gene product confirmed 84% homology with the available gene bank human sequence. CONCLUSIONS: This study proves that iNOS is expressed in human vein bypass grafts. Additionally, there is a significant elevation of iNOS message in human ACVGs compared with IVG or normal SV. This difference may be the result of the unique vascular beds supplied by these grafts. Ultimately, manipulation of iNOS expression may lead to therapies to alleviate IH in these grafts.

    Original languageEnglish (US)
    Pages (from-to)177-180
    Number of pages4
    JournalAmerican Journal of Surgery
    Volume174
    Issue number2
    DOIs
    StatePublished - Jan 1 1997

    Fingerprint

    Nitric Oxide Synthase Type II
    Veins
    Transplants
    Tunica Intima
    Glyceraldehyde
    Hyperplasia
    Nitric Oxide
    Vascular Patency
    Gene Expression
    Saphenous Vein
    Genes
    Reverse Transcription
    Blood Vessels
    RNA

    All Science Journal Classification (ASJC) codes

    • Surgery

    Cite this

    Dattilo, J., Dattilo, M. P. M., Spratt, J. A., Matsuura, J., Yager, D. R., & Makhoul, R. G. (1997). Inducible nitric oxide synthase expression in human vein grafts. American Journal of Surgery, 174(2), 177-180. https://doi.org/10.1016/S0002-9610(97)90078-7

    Inducible nitric oxide synthase expression in human vein grafts. / Dattilo, Jeffery; Dattilo, Mary Peace M.; Spratt, John A.; Matsuura, John; Yager, Dorne R.; Makhoul, Raymond G.

    In: American Journal of Surgery, Vol. 174, No. 2, 01.01.1997, p. 177-180.

    Research output: Contribution to journalArticle

    Dattilo, J, Dattilo, MPM, Spratt, JA, Matsuura, J, Yager, DR & Makhoul, RG 1997, 'Inducible nitric oxide synthase expression in human vein grafts', American Journal of Surgery, vol. 174, no. 2, pp. 177-180. https://doi.org/10.1016/S0002-9610(97)90078-7
    Dattilo J, Dattilo MPM, Spratt JA, Matsuura J, Yager DR, Makhoul RG. Inducible nitric oxide synthase expression in human vein grafts. American Journal of Surgery. 1997 Jan 1;174(2):177-180. https://doi.org/10.1016/S0002-9610(97)90078-7
    Dattilo, Jeffery ; Dattilo, Mary Peace M. ; Spratt, John A. ; Matsuura, John ; Yager, Dorne R. ; Makhoul, Raymond G. / Inducible nitric oxide synthase expression in human vein grafts. In: American Journal of Surgery. 1997 ; Vol. 174, No. 2. pp. 177-180.
    @article{ebf9bbdf96574d949652dd92b92e4719,
    title = "Inducible nitric oxide synthase expression in human vein grafts",
    abstract = "BACKGROUND: The patency of vascular reconstructive procedures is limited by the development of intimal hyperplasia (IH). Nitric oxide (NO) seems to be beneficial in abrogating this process. Currently, there is little information concerning inducible nitric oxide synthase (INOS), the enzyme responsible for NO synthesis, and human vein grafts. The purpose of this study was to examine iNOS gene expression in human aortocoronary vein grafts (ACVG) and infrainguinal vein bypass grafts (IVG). METHODS: Nonthrombosed sections from ACVG (n = 5), IVG (n = 5), and control saphenous vein (SV; n = 4) were harvested and processed for RNA isolation. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was performed on samples using 32P radioactively end labeled primers. Glyceraldehyde-3- phosphatedehydrogenase (GAPDH) was the internal control, and results were expressed as iNOS pmol/ GAPDH pmol. RESULTS: There was a significant increase in the iNOS gene expression in the ACVG (0.049 ± 0.01) when compared with IVG (0.019 ± 0.001) or normal SV (0.011 ± 0.002; P ≤0.05). There was no significant difference between normal vein and the infrainguinal grafts. Sequencing of a fragment of the amplified 428 bp gene product confirmed 84{\%} homology with the available gene bank human sequence. CONCLUSIONS: This study proves that iNOS is expressed in human vein bypass grafts. Additionally, there is a significant elevation of iNOS message in human ACVGs compared with IVG or normal SV. This difference may be the result of the unique vascular beds supplied by these grafts. Ultimately, manipulation of iNOS expression may lead to therapies to alleviate IH in these grafts.",
    author = "Jeffery Dattilo and Dattilo, {Mary Peace M.} and Spratt, {John A.} and John Matsuura and Yager, {Dorne R.} and Makhoul, {Raymond G.}",
    year = "1997",
    month = "1",
    day = "1",
    doi = "10.1016/S0002-9610(97)90078-7",
    language = "English (US)",
    volume = "174",
    pages = "177--180",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Inducible nitric oxide synthase expression in human vein grafts

    AU - Dattilo, Jeffery

    AU - Dattilo, Mary Peace M.

    AU - Spratt, John A.

    AU - Matsuura, John

    AU - Yager, Dorne R.

    AU - Makhoul, Raymond G.

    PY - 1997/1/1

    Y1 - 1997/1/1

    N2 - BACKGROUND: The patency of vascular reconstructive procedures is limited by the development of intimal hyperplasia (IH). Nitric oxide (NO) seems to be beneficial in abrogating this process. Currently, there is little information concerning inducible nitric oxide synthase (INOS), the enzyme responsible for NO synthesis, and human vein grafts. The purpose of this study was to examine iNOS gene expression in human aortocoronary vein grafts (ACVG) and infrainguinal vein bypass grafts (IVG). METHODS: Nonthrombosed sections from ACVG (n = 5), IVG (n = 5), and control saphenous vein (SV; n = 4) were harvested and processed for RNA isolation. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was performed on samples using 32P radioactively end labeled primers. Glyceraldehyde-3- phosphatedehydrogenase (GAPDH) was the internal control, and results were expressed as iNOS pmol/ GAPDH pmol. RESULTS: There was a significant increase in the iNOS gene expression in the ACVG (0.049 ± 0.01) when compared with IVG (0.019 ± 0.001) or normal SV (0.011 ± 0.002; P ≤0.05). There was no significant difference between normal vein and the infrainguinal grafts. Sequencing of a fragment of the amplified 428 bp gene product confirmed 84% homology with the available gene bank human sequence. CONCLUSIONS: This study proves that iNOS is expressed in human vein bypass grafts. Additionally, there is a significant elevation of iNOS message in human ACVGs compared with IVG or normal SV. This difference may be the result of the unique vascular beds supplied by these grafts. Ultimately, manipulation of iNOS expression may lead to therapies to alleviate IH in these grafts.

    AB - BACKGROUND: The patency of vascular reconstructive procedures is limited by the development of intimal hyperplasia (IH). Nitric oxide (NO) seems to be beneficial in abrogating this process. Currently, there is little information concerning inducible nitric oxide synthase (INOS), the enzyme responsible for NO synthesis, and human vein grafts. The purpose of this study was to examine iNOS gene expression in human aortocoronary vein grafts (ACVG) and infrainguinal vein bypass grafts (IVG). METHODS: Nonthrombosed sections from ACVG (n = 5), IVG (n = 5), and control saphenous vein (SV; n = 4) were harvested and processed for RNA isolation. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was performed on samples using 32P radioactively end labeled primers. Glyceraldehyde-3- phosphatedehydrogenase (GAPDH) was the internal control, and results were expressed as iNOS pmol/ GAPDH pmol. RESULTS: There was a significant increase in the iNOS gene expression in the ACVG (0.049 ± 0.01) when compared with IVG (0.019 ± 0.001) or normal SV (0.011 ± 0.002; P ≤0.05). There was no significant difference between normal vein and the infrainguinal grafts. Sequencing of a fragment of the amplified 428 bp gene product confirmed 84% homology with the available gene bank human sequence. CONCLUSIONS: This study proves that iNOS is expressed in human vein bypass grafts. Additionally, there is a significant elevation of iNOS message in human ACVGs compared with IVG or normal SV. This difference may be the result of the unique vascular beds supplied by these grafts. Ultimately, manipulation of iNOS expression may lead to therapies to alleviate IH in these grafts.

    UR - http://www.scopus.com/inward/record.url?scp=0030773215&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0030773215&partnerID=8YFLogxK

    U2 - 10.1016/S0002-9610(97)90078-7

    DO - 10.1016/S0002-9610(97)90078-7

    M3 - Article

    VL - 174

    SP - 177

    EP - 180

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 2

    ER -